Skip to main content

Xaracoll FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 17, 2020.

FDA Approved: Yes (First approved August 28, 2020)
Brand name: Xaracoll
Generic name: bupivacaine hydrochloride
Dosage form: Implant
Company: Innocoll Holdings Limited
Treatment for: Postsurgical Pain Relief Following Open Inguinal Hernia

Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant containing the local anesthetic bupivacaine indicated for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair.

  • Xaracoll is placed at the surgical site and releases bupivacaine hydrochloride through diffusion (immediately and over time) from the porous collagen implant, which dissolves over time.

Development timeline for Xaracoll

Aug 31, 2020Approval FDA Approves Xaracoll (bupivacaine hydrochloride) Implant for Acute Postsurgical Pain Relief Following Open Inguinal Hernia Repair

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.